Variations in the CYP2C19 gene lead to abnormal concentrations of drugs or drug metabolites in the body, which may lead to toxicity, risk of adverse drug reactions or impaired drug efficacy.
The Viennalab PGX-CYP2C19 StripAssay® detects genetic variants resulting in reduced or increased activity of the cytochrome P450 isoenzyme CYP2C19. It allows the discrimination between poor and rapid CYP2C19 metabolizer and in consequence helps to avoid adverse events or failure of therapy.
The Viennalab PGX-CYP2C19 StripAssay® not only tests for the 3 most common alleles, which are *2, *8 and *17. But also for 5 other alleles associated with impaired or increased enzymatic activity. Click here to see the product brochure.
Copyright © 2020 Goffin Molecular Technologies